Rituximab in autoimmune pancytopenia: a case report and review of literature

Livedo reticular associado com Anemia Hemolítica Autoimune: remissão prolongada induzida pelo Transplante de Células-Tronco do Sangue Periférico com recaída após 10 anos e restauração dos níveis de hemoglobina por rituximabe

“…Its use in AIHA has generated growing interest and the incidence of response has been high in most series including as well other immunecytopenias. [6][7][8][9][10][11] At the time of diagnosis, this medication was not available; however, we believe that the observed response is the longest reported in the literature. Almost all patients with immune cytopenias relapse after periods of time.…”

Immune Pancytopenia Associated with a Leukemic B-Cell Tumor Carrying t(14;18)(q32;q21) Translocation

“…Autoimmune hemolytic anemia (AIHA), immune thrombocytopenia, and/or immune neutropenia can develop simultaneously in the absence of any underlying cause or in association with other diseases such as autoimmune diseases, lymphoproliferative disorders, or primary immunodeficiencies (1,2). Rituximab, a monoclonal antibody for the CD20 antigen, has been introduced into the treatment of immune cytopenia with the aim to eliminate antibody-producing B cells (2)(3)(4).…”

“…Rituximab, a monoclonal antibody for the CD20 antigen, has been introduced into the treatment of immune cytopenia with the aim to eliminate antibody-producing B cells (2)(3)(4). In one retrospective series of Evans syndrome, the long-term response rate to rituximab was reported to be 64%, and the use of rituximab for corticosteroid-resistant cases was warranted (1).…”

Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome

“…Rituximab, with CD20 targeted, has not previously been a common mode of treatment for refractory AIH. Although there are documented cases of its effectiveness in AIHA and ITP, the data on effi cacy of rituximab specifi cally in AIH are limited [6][7][8][9][10][11][12] . We describe a case of severe AIH and Evans syndrome successfully treated with rituximab.…”